"Loyal has developed LOY-002, a daily pill for senior dogs that targets the metabolic drivers of aging, aiming to extend their healthy lifespan."
"The company has raised over $150 million and completed the largest clinical trial in veterinary medicine history, involving 1,300 dogs across 70 clinics."
"The FDA has signed off on LOY-002's safety and reasonable expectation of effectiveness, positioning Loyal to launch the drug as soon as next year."
"Halioua's ambitions extend beyond dogs, as successful results in canine trials could lead to similar treatments for humans in the burgeoning longevity industry."
Loyal, a startup founded by Celine Halioua, is creating LOY-002, a daily pill for senior dogs that targets aging. The company has raised over $150 million and conducted the largest veterinary clinical trial with 1,300 dogs. The FDA has approved the drug's safety and effectiveness, aiming for a launch next year at $100 monthly. Halioua also envisions extending these treatments to humans, as successful dog trials could accelerate human drug development in the $10 billion longevity market.
Read at Entrepreneur
Unable to calculate read time
Collection
[
|
...
]